221 related articles for article (PubMed ID: 26052388)
1. Alpha-1 antitrypsin deficiency and the risk of hepatocellular carcinoma in end-stage liver disease.
Antoury C; Lopez R; Zein N; Stoller JK; Alkhouri N
World J Hepatol; 2015 Jun; 7(10):1427-32. PubMed ID: 26052388
[TBL] [Abstract][Full Text] [Related]
2. Alpha-1-antitrypsin in pathogenesis of hepatocellular carcinoma.
Topic A; Ljujic M; Radojkovic D
Hepat Mon; 2012 Oct; 12(10 HCC):e7042. PubMed ID: 23162602
[TBL] [Abstract][Full Text] [Related]
3. Association of α 1 Antitrypsin Phenotype and Development of Advanced Liver Disease and Pulmonary Complications Before and After Liver Transplantation.
Abu Rmilah A; Fencl R; Watt K; Krowka M; Wiesner R; Murray D; Nyberg S; Leise M
Transplantation; 2021 Jul; 105(7):1576-1584. PubMed ID: 32732616
[TBL] [Abstract][Full Text] [Related]
4. Use of antiretroviral therapy and risk of end-stage liver disease and hepatocellular carcinoma in HIV-positive persons.
Ryom L; Lundgren JD; De Wit S; Kovari H; Reiss P; Law M; El-Sadr W; Monforte AD; Mocroft A; Smith C; Fontas E; Dabis F; Phillips A; Sabin C;
AIDS; 2016 Jul; 30(11):1731-43. PubMed ID: 26752282
[TBL] [Abstract][Full Text] [Related]
5. Heterozygosity for the alpha-1-antitrypsin Z allele in cirrhosis is associated with more advanced disease.
Schaefer B; Mandorfer M; Viveiros A; Finkenstedt A; Ferenci P; Schneeberger S; Tilg H; Zoller H
Liver Transpl; 2018 Jun; 24(6):744-751. PubMed ID: 29573137
[TBL] [Abstract][Full Text] [Related]
6. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis.
Ascha MS; Hanouneh IA; Lopez R; Tamimi TA; Feldstein AF; Zein NN
Hepatology; 2010 Jun; 51(6):1972-8. PubMed ID: 20209604
[TBL] [Abstract][Full Text] [Related]
7. Risk of development of hepatocellular carcinoma in patients with NASH-related cirrhosis.
Amarapurkar DN; Dharod M; Gautam S; Patel N
Trop Gastroenterol; 2013; 34(3):159-63. PubMed ID: 24851525
[TBL] [Abstract][Full Text] [Related]
8. Overview of Complications in Cirrhosis.
Premkumar M; Anand AC
J Clin Exp Hepatol; 2022; 12(4):1150-1174. PubMed ID: 35814522
[TBL] [Abstract][Full Text] [Related]
9. Is severe progressive liver disease caused by alpha-1-antitrypsin deficiency more common in children or adults?
Chu AS; Chopra KB; Perlmutter DH
Liver Transpl; 2016 Jul; 22(7):886-94. PubMed ID: 26946192
[TBL] [Abstract][Full Text] [Related]
10. A nationwide population-based prospective study of cirrhosis in Iceland.
Olafsson S; Rögnvaldsson S; Bergmann OM; Jonasson JG; Benitez Hernandez U; Björnsson ES
JHEP Rep; 2021 Jun; 3(3):100282. PubMed ID: 34041467
[TBL] [Abstract][Full Text] [Related]
11. alpha-1-Antitrypsin phenotypes in hepatocellular carcinoma.
Govindarajan S; Ashcavai M; Peters RL
Hepatology; 1981; 1(6):628-31. PubMed ID: 6171495
[TBL] [Abstract][Full Text] [Related]
12. Hereditary hemochromatosis: Temporal trends, sociodemographic characteristics, and independent risk factor of hepatocellular cancer - nationwide population-based study.
Haider MB; Al Sbihi A; Chaudhary AJ; Haider SM; Edhi AI
World J Hepatol; 2022 Sep; 14(9):1804-1816. PubMed ID: 36185720
[TBL] [Abstract][Full Text] [Related]
13. Lower rates of receiving model for end-stage liver disease exception and longer time to transplant among nonalcoholic steatohepatitis hepatocellular carcinoma.
Young K; Aguilar M; Gish R; Younossi Z; Saab S; Bhuket T; Liu B; Ahmed A; Wong RJ
Liver Transpl; 2016 Oct; 22(10):1356-66. PubMed ID: 27348270
[TBL] [Abstract][Full Text] [Related]
14. Hepatocytic PAS-positive diastase-resistance inclusions in the absence of alpha-1-antitrypsin deficiency--high prevalence in alcoholic cirrhosis.
Pariente EA; Degott C; Martin JP; Feldmann G; Potet F; Benhamou JP
Am J Clin Pathol; 1981 Sep; 76(3):299-302. PubMed ID: 6169273
[TBL] [Abstract][Full Text] [Related]
15. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease.
Reddy SK; Steel JL; Chen HW; DeMateo DJ; Cardinal J; Behari J; Humar A; Marsh JW; Geller DA; Tsung A
Hepatology; 2012 Jun; 55(6):1809-19. PubMed ID: 22183968
[TBL] [Abstract][Full Text] [Related]
16. Hepatic decompensation is accelerated in patients with cirrhosis and alpha-1 antitrypsin Pi∗MZ genotype.
Chen VL; Burkholder DA; Moran IJ; DiBattista JV; Miller MJ; Chen Y; Du X; Oliveri A; Cushing KC; Lok AS; Speliotes EK
JHEP Rep; 2022 Jun; 4(6):100483. PubMed ID: 35571533
[TBL] [Abstract][Full Text] [Related]
17. The risk of end stage liver disease and hepatocellular carcinoma among persons infected with hepatitis C virus: publication bias?
Goodgame B; Shaheen NJ; Galanko J; El-Serag HB
Am J Gastroenterol; 2003 Nov; 98(11):2535-42. PubMed ID: 14638360
[TBL] [Abstract][Full Text] [Related]
18. Long-term follow-up of hepatitis C infection in a large cohort of patients with inherited bleeding disorders.
Fransen van de Putte DE; Makris M; Fischer K; Yee TT; Kirk L; van Erpecum KJ; Patch D; Posthouwer D; Mauser-Bunschoten EP
J Hepatol; 2014 Jan; 60(1):39-45. PubMed ID: 23978717
[TBL] [Abstract][Full Text] [Related]
19. Hepatocytic globules in end-stage hepatic disease: relationship to alpha1-antitrypsin phenotype.
Iezzoni JC; Gaffey MJ; Stacy EK; Normansell DE
Am J Clin Pathol; 1997 Jun; 107(6):692-7. PubMed ID: 9169667
[TBL] [Abstract][Full Text] [Related]
20. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis.
Aby E; Phan J; Truong E; Grotts J; Saab S
J Clin Gastroenterol; 2019 Feb; 53(2):142-146. PubMed ID: 29912761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
